Veridex, LLC, a Johnson & Johnson Company, Raritan, NJ, USA.
Biomark Med. 2010 Aug;4(4):523-33. doi: 10.2217/bmm.10.66.
Despite advances in the management of many human cancers over the past few decades, improvements in survival are marginal, and the overall diagnosis and prognosis for cancer patients remain poor. Tailoring therapy to the individual patient has become a promising approach for maximizing efficacy and minimizing drug toxicity. Aided by major technological advances, the field of personalized medicine has become extremely active in the identification of predictive biomarkers that can guide treatment decisions and, ultimately, improve treatment outcomes. Genomics and proteomics have provided a means for molecular profiling that allows tailoring of therapy. Although implementing genomic and proteomic testing into clinical practice is still in its infancy, the rapid development of newer technologies and platforms provides hope for personalized medicine.
尽管在过去几十年中，许多人类癌症的治疗取得了进展，但生存的改善仍微不足道，癌症患者的整体诊断和预后仍然很差。为每个患者量身定制治疗方案已成为提高疗效和降低药物毒性的一种有前途的方法。在重大技术进步的辅助下，个性化医学领域在识别预测性生物标志物方面变得非常活跃，这些生物标志物可以指导治疗决策，并最终改善治疗效果。基因组学和蛋白质组学为分子谱分析提供了一种方法，可以实现治疗方案的定制。尽管将基因组学和蛋白质组学检测纳入临床实践仍处于起步阶段，但新技术和平台的快速发展为个性化医学带来了希望。
